Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > generic

: 25C-NBOH

or None

& classes: Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism

Use the filters below to narrow your results.

Qelbree (1)

Selective NET inhibitor (no significant DAT activity, distinguishes from amphetamine/methylphenidate). Also: 5HT1A receptor partial agonism, 5HT2B and 5HT7 receptor antagonism. The serotonergic actions may underlie better tolerability and possibly different efficacy spectrum than atomoxetine. (1)

ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult) (1)

Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg. (1)

100 mg, 150 mg, 200 mg extended-release capsules (can be sprinkled on food) (1)

400 mg/d (pediatric); 600 mg/d (adult) (1)

Oral (1)

ADHD symptom improvement reported within 1-2 weeks (faster than atomoxetine which takes 4-6 weeks) (1)

Daily dosing (1)

~7 hours (1)

Adequate oral bioavailability with extended-release formulation (1)

Limited data (1)

Rx, '''not a controlled substance''' (no DEA scheduling) (1)

Showing below up to 1 result in range #1 to #1.

V

Viloxazine

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"